{
  "ticker": "TLX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959431",
  "id": "02959431",
  "pages": 7,
  "price_sensitive": false,
  "date": "20250618",
  "time": "0822",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvfpd8g8ccs3.pdf",
  "summary": "- **Security Issuance Details**:  \n  - **166,483 Share Appreciation Rights (TLXAO)** issued to MD & CEO Christian Behrenbruch on 13/06/2025.  \n    - Notional exercise price: **$28.67**.  \n    - Performance-based vesting (2025\u20132027).  \n  - **2,595 Deferred Share Rights (TLXAU)** issued to same executive on same date.  \n    - Nil exercise price; service-conditioned vesting.  \n\n- **Capital Structure Update**:  \n  - Total ordinary shares (TLX) on issue: **338,248,789**.  \n  - Unquoted securities include **15.8m Share Appreciation Rights (TLXAO)** and **10,561 Deferred Share Rights (TLXAU)** post-issuance.  \n\n- **Governance**:  \n  - Issued under approved employee incentive scheme (terms in [2024 Remuneration Report](https://ir.telixpharma.com/reports)).  \n\n*No material trading or capital impact identified (routine executive remuneration issuance).*",
  "usage": {
    "prompt_tokens": 2270,
    "completion_tokens": 233,
    "total_tokens": 2503,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T22:34:45.515374"
}